

30th January, 2019

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001 Scrip Code: BSE – AJANTPHARM 532331	National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Scrip Code: NSE AJANTPHARM EQ
--	--

Re: Outcome of the Board Meeting

Dear Madam/Sir,


At the Board meeting held today, the Board has inter alia approved and taken on record Unaudited Financial results for the third quarter ended 31st December 2018. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:

- i. Press Release being issued on the Results for the third quarter ended 31st December 2018;
- ii. Unaudited Consolidated Financial Results for the third quarter ended 31st December 2018;
- iii. Limited Review Report from Auditors M/s BSR & Co. LLP on the unaudited Consolidated Financial Results for the third quarter ended 31st December 2018;
- iv. Unaudited Standalone Financial Results for the third quarter ended 31st December 2018;
- v. Limited Review Report from Auditors M/s BSR & Co. LLP on the unaudited Standalone Financial Results for the third quarter ended 31st December 2018.

Kindly note that the meeting of the Board of Directors commenced at 3.30 p.m. and concluded at 5.45 p.m. and take the above on your records.

Thanking You,

Yours faithfully,


GAURANG SHAH

AVP - Legal & Company Secretary

Encl.: a/a

Press Release**Profit After Tax at 14% of Revenue**
(3rd Quarter & 9 Months, FY 2019 Consolidated Results)

Mumbai, 30th January, 2019: Ajanta Pharma Ltd. a specialty pharmaceutical formulation company reported today its performance for the 3rd quarter & 9 months ended 31st December 2018.

Q3 FY 2019 performance highlights (compared to Q3 FY 2018)

- Income from operations at Rs. 485 cr. against Rs. 587 cr., down 17%.
- EBITDA at Rs. 107 cr. against Rs. 198 cr., down 46%; EBITDA at 22% of revenue.
- Profit after tax at Rs. 67 cr., against Rs. 147 cr., down 55%; PAT at 14% of revenue.

9 Months FY 2019 performance highlights (compared to 9 months FY 2018)

- Income from operations at Rs. 1,540 cr. against Rs. 1,601 cr., down 4%.
- EBITDA at Rs. 439 cr. against Rs. 509 cr., down 14%; EBITDA at 29% of revenue.
- Profit after tax at Rs. 298 cr., against Rs. 374 cr., down 20%; PAT at 19% of revenue.

Commenting on the results, Mr. Yogesh Agrawal, Managing Director said:

“This quarter was bit challenging for the company which was the result of pipeline filling in corresponding quarter previous year which got normalized. Our sales in all our key markets continue to post satisfactory growths reflecting strong inherent fundamentals of the brands which are built over the years. This quarter also saw significant drop in the anti-malarial business due to changing conditions of this business segment.

Operational expenses of two new additional manufacturing facilities at Dahej & Guwahati during the year also weighed on the profitability growths. As we ramp up the capacity utilization of these facilities in coming years, we expect to see the cost rationalization and better efficiency in tax.

During 9 months, we have filed 8 ANDA's and expect to file healthy no. of ANDA's in Q4 which should pave way for sound revenues on their approval and commercialization.”

India

Q3 FY 2019, India sales was Rs. 174 cr. (against Rs. 160 cr.), up 9%. 9 Months FY 2019, India sales was Rs. 531 cr. (against Rs. 481 cr.) posting growth of 10%.

As per IMS MAT December 2018, we have posted healthy growth of 16% in Cardiology (segment growth of 11%), 13% in Ophthalmology (segment growth of 9%), 9% in Dermatology (segment growth of 14%) and 20% in Pain Management (segment growth of 9%).

Exports

Q3 FY 2019, total export sales were Rs. 304 cr. (against Rs. 415 cr.) posting de-growth of 27%.

- Emerging Market branded generic sales was Rs. 188 cr. (against Rs. 250 cr.) posting 25% de-growth. Out of which:
 - Africa branded generic sales was Rs. 64 cr. (against Rs. 86 cr.) posting 26% de-growth.
 - Asia branded generic sales was Rs. 121 cr. (against Rs. 161 cr.) posting 25% de-growth.
- US generic sales was Rs. 66 cr. (against Rs. 71 cr.) posting 7% de-growth.
- Africa Institution sales was Rs. 50 cr. (against Rs. 94 cr.) posting 47% de-growth.

9 Months FY 2019, total export sales were Rs. 981 cr. (against Rs. 1,086 cr.) posting de-growth of 10%.

- Emerging Market branded generic sales was Rs. 625 cr. (against Rs. 613 cr.) posting 2% growth. Out of which:
 - Africa branded generic sales was Rs. 232 cr. (against Rs. 246 cr.) posting 6% de-growth.
 - Asia branded generic sales was Rs. 385 cr. (against Rs. 361 cr.) posting 7% growth.
- US generic sales was Rs. 207 cr. (against Rs. 152 cr.) posting 36% growth.
- Africa Institution sales was Rs. 149 cr. (against Rs. 321 cr.) posting 53% de-growth.

In US, during **9 Months** FY 2019, we received 7 ANDA final approval; 3 tentative approvals; and filed 8 ANDA with US FDA. Out of 24 final ANDA approvals, we have commercialized 21 products. We hold 4 tentative approvals and 17 ANDAs are awaiting US FDA approval. Company plans to file 10-12 ANDAs during this financial year.

R&D

During Q3 FY 2019, R&D expenses were Rs. 45 cr., (Q3 FY 2018 Rs. 43 cr.) which is 9% of operating revenue. During 9 Months FY 2019, R&D expenses were Rs. 136 cr., (9 Months FY 2018 Rs. 138 cr.) which is 9% of operating revenue.

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa. Many of company's products are 1st to market and are leading in their sub-therapeutic segments.

Company's state of the art R&D centres for formulation development and API are located at Mumbai, having a team of 850+ scientists. Company has 7 world class manufacturing facilities located in India and Mauritius.

For last 5 financial years, company has posted healthy performance with its consolidated total income growing at 15% CAGR and net profit at 19% CAGR.

For more details visit www.ajantapharma.com

For regular updates follow us on twitter– www.twitter.com/ajantapharmaltd

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

Abhineet Kumar Tel: +91 22 66061814 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331
Corporate Identity Number (CIN): L24230MH1979PLC022059

Safe Harbour Statement

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited review report on Unaudited Quarterly and Year to Date Consolidated Financial Results of Ajanta Pharma Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.

The Board of Directors of Ajanta Pharma Limited

We have reviewed the accompanying statement of unaudited consolidated financial results of Ajanta Pharma Limited and its subsidiaries (collectively referred to as 'the Group'), for the quarter ended 31 December 2018 and the year to date results for the period from 1 April 2018 to 31 December 2018, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these consolidated financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* specified under section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the consolidated financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Statement includes the unaudited financial information of the following entities:

Names of the Entities	Relationship
Ajanta Pharma (Mauritius) Ltd.	Subsidiary
Ajanta Pharma USA Inc.	Subsidiary
Ajanta Pharma Philippines Inc.	Subsidiary
Ajanta Pharma Nigeria Ltd.	Subsidiary
Ajanta Pharma (Mauritius) Intl. Ltd.	Subsidiary



B S R & Co (a partnership firm with
Registration No. BA61223) converted into
B S R & Co. LLP (a Limited Liability, Partnership
with LLP Registration No. AAB-8181)
with effect from October 14, 2013

Registered Office:
5th Floor, Lodha Excelus
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011, India

Limited review report on Unaudited Quarterly and Year to Date Consolidated Financial Results of Ajanta Pharma Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations 2015. (Continued)

Ajanta Pharma Limited

We did not review the financial information of 5 subsidiaries included in the statement of unaudited consolidated financial results and consolidated year-to-date financial results, whose unaudited financial information reflect total revenue of Rs. 152.94 crore and Rs 513.14 crore for the quarter ended 31 December 2018 and period from 1 April 2018 to 31 December 2018 respectively. This unaudited financial information of these subsidiaries have been furnished to us by the Management of the Company and our conclusion on the unaudited consolidated financial results, to the extent they have been derived from such unaudited financial information in respect of these subsidiaries, is based solely on such Management certified unaudited financial information. In our opinion and according to information and explanation given to us by the Management, these unaudited financial information are not material to Group. Our conclusion is not modified in respect of this matter.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022



Sreeja Marar

Partner

Membership No: 111410

Mumbai
30 January 2019

Statement of Consolidated Unaudited Financial Results for the quarter and nine months ended 31 December 2018

₹ in Crore

Particulars	3 months ended			9 months ended		Year Ended
	31-12-2018	30-09-2018	31-12-2017	31-12-2018	31-12-2017	31-03-2018
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income						
Revenue from operations	485.11	544.11	587.05	1,540.21	1,600.55	2,130.86
Other income	4.41	15.24	15.15	19.45	20.09	24.16
Total Income	489.52	559.35	602.20	1,559.66	1,620.64	2,155.02
Expenses						
Cost of materials consumed	81.97	94.10	87.57	265.02	264.35	378.28
Purchases of stock-in-trade	7.29	15.06	22.08	36.60	57.02	77.35
Changes in inventories of finished goods, work-in-progress and stock-in-trade	8.63	(13.23)	0.34	(23.67)	(8.72)	(49.22)
Employee benefits expense	112.78	105.75	95.22	323.31	271.32	376.47
Finance costs	0.09	0.13	0.14	0.39	0.30	0.41
Depreciation and amortisation expense	18.67	17.49	14.98	53.33	42.95	59.59
Other expenses	167.13	176.21	184.34	499.60	498.89	689.59
Total Expenses	396.56	395.51	404.67	1,154.58	1,126.11	1,532.47
Profit before tax	92.96	163.84	197.53	405.08	494.53	622.55
Tax Expense						
Current Tax	23.40	40.79	46.77	110.58	107.01	131.66
Deferred Tax	2.66	(2.34)	3.29	(3.58)	13.37	22.25
Profit for the period	66.90	125.39	147.47	298.08	374.15	468.64
Other Comprehensive Income (OCI)						
Items that will be reclassified subsequently to profit or loss	0.13	0.86	(0.75)	(2.20)	2.80	5.00
Income tax relating to Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
Items that will not to be reclassified subsequently to profit or loss	(0.50)	(0.49)	(0.04)	(1.49)	(0.13)	(1.99)
Income tax relating to items that will not be reclassified subsequently to profit or loss	0.18	0.17	0.01	0.52	0.04	0.69
Other Comprehensive Income for the year, net of tax	(0.19)	0.54	(0.78)	(3.17)	2.71	3.70
Total Comprehensive Income for the period	66.71	125.93	146.69	294.91	376.86	472.34
Paid-up Equity Share Capital (Face value of ₹ 2 each)	17.69	17.69	17.69	17.69	17.69	17.69
Other Equity						2,023.68
Earnings Per Share (Face value of ₹ 2 each)						
(a) Basic - in ₹	7.60	14.25	16.76	33.87	42.51	53.26
(b) Diluted - in ₹	7.60	14.25	16.75	33.86	42.50	53.25

Notes :

- The above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 30 January 2019.
- Statutory Auditors have carried out Limited Review of the financial results for the quarter and nine month ended 31 December 2018.
- The consolidated audited financial results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest.
- Board of Directors have approved buyback proposal, for purchase by the Company of up to 7,69,230 shares of ₹ 2 each (representing 0.87% of total paid-up equity capital) from the shareholders of the Company on a proportionate basis by way of a tender offer at a price of ₹ 1,300 per equity share for an aggregate amount not exceeding ₹ 100 crores in accordance with the provisions of the Companies Act, 2013 and the SEBI (Buy Back of Securities) Regulations, 1998.
- During the quarter, Nil (nine month 8,500) equity shares of ₹ 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011, resulting in an increase in the paid-up share capital by ₹ Nil (nine month ₹ 17,000) and securities premium by ₹ Nil (nine month ₹ 1.20 crores).
- The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals".
- There are no exceptional items.
- Company has withdrawn its appeal against the NCLT order rejecting amalgamation of Gabs Investments Private Limited with it and in view thereof, the proposed merger has been called-off. There will be no impact of the same on financial statements.
- Effective 1 July 2017, sales are recorded net of GST whereas earlier sales were recorded gross of excise duty which formed part of expenses. Hence, revenue from operations for the nine months ended 31 December 2018 are not comparable with previous period corresponding figures.
- The Standalone Financial Results are available on the company's website www.ajantapharma.com.

By order of the Board
For Ajanta Pharma Ltd.

Yogesh M. Agrawal
Managing Director

Mumbai, 30 January 2019



B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited Review Report on Unaudited Quarterly and Year to Date Standalone Financial Results of Ajanta Pharma Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors of Ajanta Pharma Limited

We have reviewed the accompanying statement of unaudited standalone financial results of Ajanta Pharma Limited for the quarter ended 31 December 2018 and the year to date results for the period from 1 April 2018 to 31 December 2018, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* specified under section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants

Firm's Registration No: 101248W/W-100022

Sreeja Marar
Partner

Membership No: 111410

Mumbai
30 January 2019

Statement of Standalone Unaudited Financial Results for the quarter and nine months ended 31 December 2018

₹ in Crore

Particulars	3 months ended			9 months ended		Year Ended
	31-12-2018	30-09-2018	31-12-2017	31-12-2018	31-12-2017	31-03-2018
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income						
Revenue from operations	451.85	465.29	500.78	1,359.09	1,367.85	1,830.45
Other income	12.97	16.93	64.69	98.96	69.26	73.01
Total Income	464.82	482.22	565.47	1,458.05	1,437.11	1,903.46
Expenses						
Cost of materials consumed	81.01	93.14	87.27	262.36	262.21	375.43
Purchases of stock-in-trade	18.05	16.19	26.34	49.11	59.57	73.01
Changes in inventories of finished goods, work-in-progress and stock-in-trade	5.48	(16.32)	4.95	(31.34)	(16.60)	(49.15)
Employee benefits expense	100.13	96.53	84.20	292.29	246.13	342.89
Finance costs	0.03	0.07	0.10	0.21	0.19	0.24
Depreciation and amortisation expense	18.28	16.86	14.34	51.70	41.22	57.14
Other expenses	116.14	133.77	144.44	372.68	387.39	541.46
Total Expenses	339.12	340.24	361.64	997.01	980.11	1,341.02
Profit before tax	125.70	141.98	203.83	461.04	457.00	562.44
Tax Expense						
Current Tax	26.84	30.97	39.92	100.18	94.00	114.60
Deferred Tax	3.39	6.91	(0.68)	10.47	13.98	20.32
Profit for the period	95.47	104.10	164.59	350.39	349.02	427.52
Other Comprehensive Income (OCI)						
Items that will not be reclassified subsequently to profit or loss	(0.50)	(0.49)	(0.04)	(1.49)	(0.13)	(1.99)
Income tax relating to items that will not be reclassified subsequently to profit or loss	0.18	0.17	0.01	0.52	0.04	0.69
Other Comprehensive Income for the year, net of tax	(0.32)	(0.32)	(0.03)	(0.97)	(0.09)	(1.30)
Total Comprehensive Income for the period	95.15	103.78	164.56	349.42	348.93	426.22
Paid-up Equity Share Capital (Face value of ₹ 2 each)	17.69	17.69	17.69	17.69	17.69	17.69
Other Equity	NA	NA	NA	NA	NA	1,913.81
Earnings Per Share (Face value of ₹ 2 each)						
(a) Basic - in ₹	10.85	11.83	18.70	39.81	39.66	48.59
(b) Diluted - in ₹	10.85	11.83	18.70	39.81	39.65	48.58

Notes :

- The above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 30 January 2019.
- Statutory Auditors have carried out Limited Review of the financial results for the quarter and nine month ended 31 December 2018.
- Board of Directors have approved buyback proposal, for purchase by the Company of up to 7,69,230 shares of ₹ 2 each (representing 0.87% of total paid-up equity capital) from the shareholders of the Company on a proportionate basis by way of a tender offer at a price of ₹ 1,300 per equity share for an aggregate amount not exceeding ₹ 100 crores in accordance with the provisions of the Companies Act, 2013 and the SEBI (Buy Back of Securities) Regulations, 1998.
- Other income includes :

	3 months ended			9 months ended		Year Ended
	31-12-2018	30-09-2018	31-12-2017	31-12-2018	31-12-2017	31-03-2018
Dividend from subsidiaries (₹ in Crore)	16.44	-	49.65	77.42	49.65	49.65

- During the quarter, Nil (nine month 8,500) equity shares of ₹ 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011, resulting in an increase in the paid-up share capital by ₹ Nil (nine month ₹ 17,000) and securities premium by ₹ Nil (nine month ₹ 1.20 crores).
- The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals".
- There are no exceptional items.
- Company has withdrawn its appeal against the NCLT order rejecting amalgamation of Gabs Investments Private Limited with it and in view thereof, the proposed merger has been called-off. There will be no impact of the same on financial statements.
- Effective 1 July 2017, sales are recorded net of GST whereas earlier sales were recorded gross of excise duty which formed part of expenses. Hence, revenue from operations for the nine months ended 31 December 2018 are not comparable with previous period corresponding figures.

By order of the Board
For Ajanta Pharma Ltd.

Yogesh M. Agrawal
Managing Director

Mumbai, 30 January 2019

